Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 May 2025
US President Donald Trump's administration slashed cancer research funding by 31% in the first three months of 2025 compared to the same period last year, according to a Senate report released Tuesday that accuses the White ...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
For the first time in humans, a chemotherapy drug reaches the brain.
2.
unhealthy sleeping habits and the risk of esophageal adenocarcinoma.
3.
FDA Expands Durvalumab Label to Operable Lung Cancer
4.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
5.
A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.
1.
The Benefits of Understanding Haptoglobin High: What You Need to Know
2.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
3.
What are Acanthocytes? Understanding the Role of Spiky Red Blood Cells
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Updates on the First Line Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge